SignaBlok, Inc, P.O. Box 4064, Shrewsbury, MA, 01545, United States.
Biochimie. 2022 Apr;195:86-89. doi: 10.1016/j.biochi.2021.11.005. Epub 2021 Nov 15.
During co-evolution with their hosts, many viruses have evolved a membrane fusion mechanism to facilitate host cell entry. Examples are human immunodeficiency virus type 1 (HIV-1) and severe acute respiratory syndrome coronaviruses 1 and 2 (SARS-CoV-1 and SARS-CoV-2). These viruses can also infect immune cells (e.g., T cells), providing one of the possible mechanisms for the T cell lymphopenia observed in patients with these infections. Previously, we hypothesized and confirmed in vivo that like HIV-1, SARS-CoV-1 can use its fusion domain not only to enter the T cell but also to directly inhibit T cell receptor signaling. Here, based on the analysis of available structural and clinical data, we hypothesize that SARS-CoV-2 may use a similar "disarm the alarm" strategy to suppress immune responses. We also discuss the implications of this hypothesis for better understanding coronavirus disease 2019 (COVID-19) pathology, developing effective COVID-19 vaccines and improving clinical outcomes for COVID-19 patients.
在与宿主共同进化的过程中,许多病毒已经进化出一种膜融合机制,以促进宿主细胞进入。人类免疫缺陷病毒 1 型(HIV-1)和严重急性呼吸系统综合征冠状病毒 1 型和 2 型(SARS-CoV-1 和 SARS-CoV-2)就是例子。这些病毒也可以感染免疫细胞(例如 T 细胞),为这些感染患者中观察到的 T 细胞淋巴细胞减少症提供了可能的机制之一。此前,我们假设并在体内证实,与 HIV-1 一样,SARS-CoV-1 不仅可以利用其融合结构域进入 T 细胞,还可以直接抑制 T 细胞受体信号。在这里,我们根据现有结构和临床数据的分析,假设 SARS-CoV-2 可能使用类似的“解除警报”策略来抑制免疫反应。我们还讨论了这一假设对更好地理解 2019 年冠状病毒病(COVID-19)病理学、开发有效的 COVID-19 疫苗和改善 COVID-19 患者临床结局的意义。